Enlivex Ltd.
$0.88
▼
-1.07%
2026-04-21 06:38:03
www.enlivex.com
NCM: ENLV
Explore Enlivex Ltd. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$207.92 M
Current Price
$0.88
52W High / Low
$2.1 / $0.66
Stock P/E
—
Book Value
$8.15
Dividend Yield
—
ROCE
-0.65%
ROE
1.26%
Face Value
—
EPS
$25.48
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
34
Beta
1.68
Debt / Equity
0.03
Current Ratio
193.24
Quick Ratio
193.24
Forward P/E
-1.23
Price / Sales
—
Enterprise Value
$223.13 M
EV / EBITDA
-15.21
EV / Revenue
—
Rating
Buy
Target Price
$20
EPS Forecast (FY)
—
Pros
- Healthy return on equity.
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Xencor, Inc. | $12.8 | — | $941.6 M | — | -22.77% | -14.07% | $18.69 / $6.92 | $8.84 |
| 2. | iBio, Inc. | $1.97 | — | $70.3 M | — | -108.92% | -70.22% | $3.82 / $0.56 | $1.88 |
| 3. | ACADIA Pharmaceuticals Inc. | $22.09 | 9.63 | $3.77 B | — | 8.14% | 39.89% | $28.35 / $14.08 | $7.21 |
| 4. | Xilio Therapeutics, Inc. | $8.45 | — | $49.46 M | — | -42.66% | -1.33% | $16.52 / $6.47 | $7.79 |
| 5. | Soligenix, Inc. | $1.38 | — | $14.22 M | — | -213.96% | -2.35% | $6.23 / $1 | $0.77 |
| 6. | AnaptysBio, Inc. | $50.95 | — | $1.46 B | — | 14.7% | -24.49% | $73.3 / $17.11 | $1.33 |
| 7. | MacroGenics, Inc. | $3.48 | — | $228.17 M | — | -34.08% | -86.94% | $3.88 / $1.11 | $0.88 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M | 0 M | — |
| Operating Profit | -5.86 M | -2.56 M | -3.08 M | -3.5 M | -4.88 M | — |
| Net Profit | 1.24 B | -2.21 M | -1.87 M | -3.45 M | -5.18 M | — |
| EPS in Rs | 5.19 | -0.01 | -0.01 | -0.01 | -0.02 | -0.12 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M |
| Operating Profit | -15 M | -14.93 M | -25.15 M | -25.8 M |
| Net Profit | 1.24 B | -15.01 M | -29.07 M | -31.06 M |
| EPS in Rs | 5.16 | -0.06 | -0.12 | -0.13 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 2.33 B | 27.69 M | 36.83 M | 67.64 M |
| Total Liabilities | 392.05 M | 4.1 M | 6.75 M | 10.8 M |
| Equity | 1.93 B | 23.59 M | 30.08 M | 56.84 M |
| Current Assets | 1.74 B | 25.99 M | 33.76 M | 52.33 M |
| Current Liabilities | 9.02 M | 3.8 M | 6.06 M | 6.61 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -10.42 M | -13.01 M | -23.52 M | -23.95 M |
| Investing CF | -1.32 M | 9.06 M | -25.97 M | 62.52 M |
| Financing CF | 10.38 M | 6.45 M | 0.36 M | 0.15 M |
| Free CF | -10.48 M | -13.11 M | -23.76 M | -32.08 M |
| Capex | -0.07 M | -0.1 M | -0.24 M | -8.12 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | — | — | — | — |
| Earnings Growth % | 48.35% | 6.41% | — | — |
| Profit Margin % | — | — | — | — |
| Operating Margin % | — | — | — | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | — | — | — | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.